These discoveries led to therapeutic development of G-CSF (Granulocyte Colony-Stimulating Factor) [42], which has vastly improved the management of patients with malignancies and hematologic disorders, including congenital neutropenia. The gene discussed is CSF3; the disease is hematologic disorder.